---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Pathophysiology"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Pathophysiology. Topics: Estrogen receptor expression and dependence on estrogen receptor signaling, Ligand-dependent estrogen receptor activation, Activation function domains AF-1 and AF-2, AF-1 activity and incomplete antagonism by selective estrogen receptor modulators, and 14 further topics. 18 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/pathophysiology"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Estrogen receptor expression and dependence on estrogen receptor signaling

> “Upon activation by oestrogen, ER executes a transcriptional programme that drives proliferation and expansion of the mammary epithelia during puberty”
> “~70–80% of tumours that emerge from the mammary gland express ER and harbour some dependence on ER signalling for proliferation”
> “Although most ER+ tumours initially appear sensitive to anti-oestrogen agents, resistance can develop over time, characterized by clinical relapse, which typically involves the emergence of genetic and epigenetic alterations that allow for reactivation of ER signalling”

Source: [Will et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529099/)

<a id="topic-2.2.1.4-2"></a>

### Ligand-dependent estrogen receptor activation

> “Upon binding to estrogen, the estrogen receptor (ER) dimerizes and translocates to the nucleus, where ER dimers bind coactivators (CoA) to form a transcriptionally active ER complex.”

Source: [Hanker et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169993/)

<a id="topic-2.2.1.4-3"></a>

### Activation function domains AF-1 and AF-2

> “ER consists of two transcriptional activation domains, the N-terminal ligand-independent activation function (AF)-1 and the C-terminal ligand-dependent AF-2 domains, a ligand-binding domain (LBD) also residing in the C-terminal region, and the DNA-binding and hinge domains, positioned in the core of the protein.”

Source: [Jeselsohn et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4911210/)

<a id="topic-2.2.1.4-4"></a>

### AF-1 activity and incomplete antagonism by selective estrogen receptor modulators

> “SERMs still allow for the engagement of ER with chromatin and therefore do not inhibit transcription driven by the N-terminal ER activation function-1 (AF1) domain”
> “As AF1 activity is sensitive to various cellular inputs, the impact of SERMs on ER transcriptional output depends on the tissue environment”
> “Selective ER degraders inhibit both LBD and AF1 domains by preventing recruitment of co-activators, immobilizing and destabilizing ER, leading to degradation.”

Source: [Will et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529099/)

<a id="topic-2.2.1.4-5"></a>

### ESR1 ligand-binding domain mutations in the AF-2 region

> “All ESR1 mutations were located within the LBD/activation function-2 (AF-2) domain of the receptor and the majority occurred specifically at amino acids 537 and 538 of helix 12”
> “Consistent with this model, mutant receptors drive ER-dependent transcription and proliferation in the absence of hormone and reduce the efficacy of ER antagonists.”

Source: [Toy et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3903423/)

<a id="topic-2.2.1.4-6"></a>

### Constitutive activity and reduced drug binding of mutant estrogen receptor

> “Whereas wild-type ESR1 (ESR1-WT) is bound by estrogen ligand to enable coactivator recruitment, LBD-mutated ESR1 (ESR1-MUT) is constitutively active and thus unaffected by AI depletion of estrogen”
> “For tamoxifen, ESR1-MUT has up to 30-fold decreased binding affinity (varying by specific mutation) and requires higher doses to inhibit transactivation function and cell proliferation”
> “For fulvestrant, ESR1-MUT has up to 40-fold decreased binding affinity and, like tamoxifen, requires an increased dose by an order of magnitude to inhibit transactivation function and cell expansion in culture and xenograft models”

Source: [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)

<a id="topic-2.2.1.4-7"></a>

### ESR1 mutations acquired under aromatase inhibitor therapy for metastatic disease

> “ESR1 mutations were found exclusively in patients with estrogen receptor positive breast cancer previously exposed to AI.”
> “ESR1 mutation prevalence differed markedly between patients that were first exposed to AI during the adjuvant and metastatic settings (5.8% (3/52) vs 36.4% (16/44) respectively, p=0.0002).”
> “ESR1 mutations are rarely acquired during adjuvant AI therapy, but are commonly selected by therapy for metastatic disease”

Source: [Schiavon et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4998737/)

<a id="topic-2.2.1.4-8"></a>

### Prevalence of ESR1 mutations by prior endocrine therapy setting

> “The prevalence of ESR1 mutations in patients depends on prior duration and setting of endocrine therapy.”
> “Approximately 20–40% of patients who have received aromatase inhibition (AI) for MBC have ESR1 mutations, with prevalence varying by sites of metastatic disease”
> “Thus, ESR1 mutations in HR-positive breast cancer occur almost exclusively after AI in the metastatic setting.”

Source: [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)

<a id="topic-2.2.1.4-9"></a>

### Prevalence of ESR1 mutations in plasma after aromatase inhibitor exposure in BOLERO-2

> “Of 541 evaluable patients, 156 (28.8%) had ESR1 mutation D538G (21.1%) and/or Y537S (13.3%), and 30 had both.”

Source: [Chandarlapaty et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5063698/)

<a id="topic-2.2.1.4-10"></a>

### Prevalence of ESR1 mutations by line of therapy in real-world genomic testing

> “ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%).”
> “the prevalence of ESR1mut in TBx collected within 60 days before or after the initiation of 1st, 2nd, and 3rd lines of therapy was 8.1% (n = 175/2,154), 27.1% (n = 73/269), and 33.3% (n = 72/216), respectively.”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

<a id="topic-2.2.1.4-11"></a>

### Prevalence of ESR1 mutations before and after endocrine therapy

> “which are virtually absent in primary breast cancer but highly prevalent (20–40%) in anti-oestrogen-treated metastatic disease”

Source: [Will et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529099/)

<a id="topic-2.2.1.4-12"></a>

### ESR1 mutation as one of several endocrine resistance mechanisms

> “About 50% of endocrine resistance cases are associated with an ESR1 mutation; other mechanisms, increasingly uncovered, include alterations in the PI3K-AKT-mTORC1, RAS-MAPK, and CDK4/6-RB-E2F pathways, and ESR1 loss, amplification, and translocation”
> “ESR1 fusions are rare but exhibit complete resistance to treatments targeting the LBD of ESR1 such as selective estrogen receptor modulators (SERMs) and degraders (SERDs), as these fusions lack the LBD”

Source: [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)

<a id="topic-2.2.1.4-13"></a>

### Ligand-independent estrogen receptor reactivation through growth factor signaling

> “Instead, endocrine resistance is commonly driven by ligand-independent ER reactivation”
> “Upon adaptation and/or resistance to antiestrogens, growth factor-driven mitogenic and survival pathways (i.e., PI3K/mTOR, RAS/RAF/MEK/ERK) can drive reactivation of ER transcription in the absence of estradiol.”
> “These resistant tumors are typically dependent upon both the aberrantly activated survival pathway and ER, and in most cases combined inhibition of both pathways is more effective”

Source: [Hanker et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169993/)

<a id="topic-2.2.1.4-14"></a>

### PI3K, AKT, and PTEN pathway alterations

> “Components of the PI3K pathway (including PIK3CA, PTEN, and AKT1) are frequently mutated in ER+ breast cancers”
> “Aberrant activation of the PI3K pathway promotes acquired resistance to estrogen depletion in preclinical models”
> “AKT1 and PTEN mutations are more frequent in advanced/metastatic ER+ breast cancers”

Source: [Hanker et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169993/)

<a id="topic-2.2.1.4-15"></a>

### Prevalence of PI3K, AKT, and PTEN alterations by line of therapy

> “1002 (17.3%) TBx and 503 (30.1%) LBx had an ESR1mut detected; 2,442 (42.2%) TBx and 564 (33.8%) LBx had a PIK3CAmut detected; 289 (5%) TBx and 70 (4.2%) LBx had an AKT1mut detected; and 602 (10.4%) TBx and 41 (2.5%) LBx had a PTEN alteration (mut or loss) detected.”
> “We observed that the prevalence of an alteration in the PI3K/AKT pathway in TBx collected in 1st, 2nd, and 3rd lines of therapy was 55.1% (n = 1,186/2,154), 48.3% (n = 130/269), and 54.6% (n = 118/216), respectively.”
> “Among patients with TBx in 1st (n = 2154), 2nd (n = 269), and 3rd (n = 216) lines, both ESR1mut and a PI3K/AKT pathway GA were detected in 4.4% (95), 8.2% (22), and 17.1% (37), respectively”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

<a id="topic-2.2.1.4-16"></a>

### Resistance to CDK4/6 inhibitors

> “Some of the somatic alterations described above have also been shown to promote resistance to CDK4/6i, including FGFR1 amplification, PTEN alterations, and ERBB2 mutations”
> “In contrast, RB1 and FAT1 alterations appear to be exclusively associated with resistance to CDK4/6 inhibitors and less to antiestrogens alone”
> “Acquired hotspot mutations in PIK3CA have been reported following progression on either fulvestrant alone or in combination with CDK4/6 inhibitors (CDK4/6i)”

Source: [Hanker et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169993/)

<a id="topic-2.2.1.4-17"></a>

### Estrogen receptor-independent growth and loss of estrogen receptor expression

> “Loss of ER expression occurs in a minority (~10%) of endocrine-resistant breast cancers”
> “In addition to ER, RTKs activate other transcription factors that promote ER-independent survival.”
> “Indeed, Razavi et al. reported that 60% of endocrine-resistant MBC lacked known somatic drivers of resistance”

Source: [Hanker et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169993/)

<a id="topic-2.2.1.4-18"></a>

### Estrogen receptor-dependent and estrogen receptor-independent routes of resistance

> “Still, these may be thought of as either (1) reactivating ER signalling despite drug administration or (2) bypassing ER to drive another oncogenic programme”
> “Interestingly, resistance mechanisms relating to active ER signalling are more typically observed in tumours that manifest with a period of apparent sensitivity followed by resistance, that is, resistance that is acquired under the pressure of therapy, whereas ER-independent mechanisms often appear in tumours that are intrinsically resistant.”
> “Pink and red: other cancers lose dependency on ER altogether.”

Source: [Will et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529099/)

Additional sources: [Fribbens et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27269946/); [Cabel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41260263/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
